| Статус: | Recruiting |
| Фаза: | Phase 4 |
| Начало: | 24 января 2024 г. |
| Окончание: | 31 декабря 2026 г. |
| Описание: | Study of efficacy and safety of Vespireit, prolonged-release tablets, 15 mg (Valenta Pharm JSC, Russia) in comparison with Arlevert, tablets, 40 mg + 20 mg (Menarini International Operations Luxembourg S.A., Luxembourg) in patients with autonomic dysfunction syndrome accompanied by functional vertigo. |
| смотреть на ClinicalTrials.gov |